Publications by authors named "Luciano Carestia"
Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK mNSCLC) by increasing long-term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18-45 years old).
View Article and Find Full Text PDFArticle Synopsis
- An HIV-positive woman in her 20s unexpectedly became pregnant while undergoing treatment with alectinib for stage IV non-small-cell lung carcinoma, despite being advised to use effective contraception.
- A complete response to the cancer treatment was noted when the pregnancy was discovered, leading to the decision to temporarily stop alectinib as the patient opted to continue the pregnancy.
- The pregnancy proceeded without complications, resulting in the healthy vaginal delivery of a female baby, and after 34 months of follow-up, the mother remained in remission and the child's development was normal.